A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases
Cancer - Gastro/ Colorectal
Principal Investigator: Gazala N Khan, MD
To evaluate and compare the efficacy and safety of regorafenib versus placebo in subjects with colorectal cancer (CRC) after curative resection of liver metastasis and completion of all planned chemotherapy.
- Have a history of a primary adenocarcinoma of the colon and / or rectum
- Have a history of Stage IV Colorectal Cancer (CRC) with metastases to the liver only
- Have received at least 3 months of neoadjuvant, adjuvant, or perioperative chemotherapy, including a fluoropyrimidine and either oxaliplatin or irinotecan or both for subjects with initial Stage IV CRC which were treated with surgery with curative intent for both primary and metastatic lesions
Please contact us for a complete list of eligibility criteria.